National Institute of Mental Health; Notice of Closed Meeting, 56027 [2023-17711]
Download as PDF
<![CDATA[
Federal Register / Vol. 88, No. 158 / Thursday, August 17, 2023 / Notices
ddrumheller on DSK120RN23PROD with NOTICES1
hallmark feature of type 2 diabetes
mellitus (T2DM) is the accumulation of
islet amyloid polypeptide fibrils in
pancreatic islets. Such accumulations
form amyloid plaques, referred to as
islet amyloidosis. Amyloidosis due to
aggregation of amyloid-b is key
pathogenic event in AD, whereas
aggregation of mature islet amyloid
polypeptide (IAPP37) in human islet
leads to b-cell dysfunction. Researchers
at NIA used a bioinformatic approach to
identify two novel islet amyloid
polypeptide isoforms: IAPPb, encoding
an elongated propeptide and nonaggregating IAPPg, which is processed to
mature IAPP25 instead of IAPP37. They
developed a quantitative selective
reaction monitoring (SRM) proteomic
assay to measure the isoform peptide
levels in human clinical plasma and
CSF from individuals with early AD and
found that their levels were significantly
reduced. Further, mature IAPP25 derived
from IAPPg isoform inhibits fibrillation
of IAPP and amyloid-b efficiently in
vitro.
Potential Commercial Applications:
The novel IAPPb and IAPPg isoforms are
potential peptidyl therapeutics to
counteract with amyloid forming IAPP
and amyloid-b in treatments of diabetes
and Alzheimer’s disease and serve as
blood-based biomarkers for Alzheimer’s
disease.
Competitive Advantages:
• Peptide based anti-amyloid
medicine.
• Potential market applications for
neurodegenerative diseases.
Development Stage: Pre-clinical (in
vivo validation).
Publications: Liu, Q.-R., et al. Novel
Hominid-Specific IAPP Isoforms:
Potential Biomarkers of Early
Alzheimer’s Disease and Inhibitors of
Amyloid Formation. (PMID 36671553)
at https://pubmed.ncbi.nlm.nih.gov/
36671553/.
Meng, Lanxia, et al. Islet amyloid
polypeptide triggers a-synuclein
pathology in Parkinson’s disease. (PMID
37150314)
Dated: August 11, 2023.
Richard U. Rodriguez,
Associate Director, Technology Transfer
Center, National Cancer Institute.
[FR Doc. 2023–17673 Filed 8–16–23; 8:45 am]
BILLING CODE 4140–01–P
VerDate Sep<11>2014
21:36 Aug 16, 2023
Jkt 259001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Human Genome Research
Institute; Notice of Closed Meeting
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Human
Genome Research Institute Initial Review
Group; Genome Research Study Section
GNOM–G—CEGS.
Date: November 2–3, 2023.
Time: 10:00 a.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Human Genome Research
Institute, National Institutes of Health, 6700B
Rockledge Drive, Room 3180, Bethesda, MD
20892 (Virtual Meeting).
Contact Person: Sarah Jo Wheelan, Ph.D.,
Scientific Review Officer, Scientific Review
Branch, National Human Genome Research
Institute, National Institutes of Health, 6700B
Rockledge Drive, Room 3180, Bethesda, MD
20892, (301) 402–8823, wheelansj@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.172, Human Genome
Research, National Institutes of Health, HHS)
Dated: August 14, 2023.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
56027
552b(c)(6), title 5 U.S.C., as amended for
the review, discussion, and evaluation
of individual intramural programs and
projects conducted by the National
Institute Of Mental Health, including
consideration of personnel
qualifications and performance, and the
competence of individual investigators,
the disclosure of which would
constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Board of Scientific
Counselors; National Institute of Mental
Health.
Date: September 20–22, 2023.
Time: September 20, 2023, 1:00 p.m. to
5:15 p.m.
Agenda: To review and evaluate personnel
qualifications and performance, and
competence of individual investigators.
Place: Porter Neuroscience Research
Center, Building 35A, 35 Convent Drive,
Bethesda, MD 20892.
Time: September 21, 2023, 10:00 a.m. to
5:55 p.m.
Agenda: To review and evaluate personnel
qualifications and performance, and
competence of individual investigators.
Place: Porter Neuroscience Research
Center, Building 35A, 35 Convent Drive,
Bethesda, MD 20892.
Time: September 22, 2023, 10:00 a.m. to
3:10 p.m.
Agenda: To review and evaluate personnel
qualifications and performance, and
competence of individual investigators.
Place: Porter Neuroscience Research
Center, Building 35A, 35 Convent Drive,
Bethesda, MD 20892.
Contact Person: Jennifer E. Mehren, Ph.D.,
Scientific Advisor, Division of Intramural
Research Programs, National Institute of
Mental Health, NIH, 35A Convent Drive,
Room GE 412, Bethesda, MD 20892–3747,
301–496–3501, mehrenj@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.242, Mental Health Research
Grants, National Institutes of Health, HHS)
[FR Doc. 2023–17713 Filed 8–16–23; 8:45 am]
Dated: August 14, 2023.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
BILLING CODE 4140–01–P
[FR Doc. 2023–17711 Filed 8–16–23; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Mental Health;
Notice of Closed Meeting
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of a
meeting of the Board of Scientific
Counselors, National Institute of Mental
Health.
The meeting will be closed to the
public as indicated below in accordance
with the provisions set forth in section
PO 00000
Frm 00032
Fmt 4703
Sfmt 4703
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Collaboration Opportunity To Develop
a Vaccine Against Nicotine or
Arecoline
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The Cancer Prevention
Program of the National Cancer Institute
(NCI) is seeking a partner in the private
SUMMARY:
E:\FR\FM\17AUN1.SGM
17AUN1
]]>Agencies
[Federal Register Volume 88, Number 158 (Thursday, August 17, 2023)]
[Notices]
[Page 56027]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-17711]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Mental Health; Notice of Closed Meeting
Pursuant to section 1009 of the Federal Advisory Committee Act, as
amended, notice is hereby given of a meeting of the Board of Scientific
Counselors, National Institute of Mental Health.
The meeting will be closed to the public as indicated below in
accordance with the provisions set forth in section 552b(c)(6), title 5
U.S.C., as amended for the review, discussion, and evaluation of
individual intramural programs and projects conducted by the National
Institute Of Mental Health, including consideration of personnel
qualifications and performance, and the competence of individual
investigators, the disclosure of which would constitute a clearly
unwarranted invasion of personal privacy.
Name of Committee: Board of Scientific Counselors; National
Institute of Mental Health.
Date: September 20-22, 2023.
Time: September 20, 2023, 1:00 p.m. to 5:15 p.m.
Agenda: To review and evaluate personnel qualifications and
performance, and competence of individual investigators.
Place: Porter Neuroscience Research Center, Building 35A, 35
Convent Drive, Bethesda, MD 20892.
Time: September 21, 2023, 10:00 a.m. to 5:55 p.m.
Agenda: To review and evaluate personnel qualifications and
performance, and competence of individual investigators.
Place: Porter Neuroscience Research Center, Building 35A, 35
Convent Drive, Bethesda, MD 20892.
Time: September 22, 2023, 10:00 a.m. to 3:10 p.m.
Agenda: To review and evaluate personnel qualifications and
performance, and competence of individual investigators.
Place: Porter Neuroscience Research Center, Building 35A, 35
Convent Drive, Bethesda, MD 20892.
Contact Person: Jennifer E. Mehren, Ph.D., Scientific Advisor,
Division of Intramural Research Programs, National Institute of
Mental Health, NIH, 35A Convent Drive, Room GE 412, Bethesda, MD
20892-3747, 301-496-3501, [email protected].
(Catalogue of Federal Domestic Assistance Program Nos. 93.242,
Mental Health Research Grants, National Institutes of Health, HHS)
Dated: August 14, 2023.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2023-17711 Filed 8-16-23; 8:45 am]
BILLING CODE 4140-01-P
